News | News By Subject | News by Disease News By Date | Search News

Psoriasis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
FDA Approval of Siliq for Psoriasis—How Will the Drug Perform in an Already Overcrowded Market?     2/22/2017
A Look at Amgen (AMGN) and Its $10 Billion Flop Onyx (AMGN)     11/3/2016
This Experimental Drug Could be Johnson & Johnson (JNJ)'s Next Blockbuster     10/7/2016
Sun Pharma (SUNPHARMA.NS), Almirall in $50 Million Psoriasis Drug Tie-Up     7/28/2016
FDA Panel Says Valeant (VRX)'s Psoriasis Med Should be Approved with Risk Plan     7/20/2016
FDA Panel Divided on Valeant (VRX)'s Psoriasis Drug Suicide Risk     7/18/2016
AbbVie (ABBV) Shows Off Positive HUMIRA Phase III Data in Moderate to Severe Fingernail Psoriasis     7/7/2016
Bay Area's XenoPort (XNPT) Snags Psoriasis and MS Deal Worth $490 Million+ from Dr. Reddy's Laboratories Ltd. (RDY)     3/28/2016
Eli Lilly (LLY) Wins FDA Approval for Psoriasis Drug Taltz     3/23/2016
Samsung Bioepis, Biogen (BIIB) Biosimilar is About to Take a Huge Chunk of Pfizer (PFE)'s Profits     11/20/2015
FDA Rejects Expanded Approval of Pfizer (PFE)'s Arthritis Drug Xeljanz     10/15/2015
Top 10 Best-Selling Biotech Drugs     10/2/2015
XenoPort (XNPT)'s Shares Jump After Psoriasis Treatment Meets Phase II Primary Endpoint     9/15/2015
AstraZeneca PLC (AZN) Inks $445 Million Psoriasis Drug Pact With Valeant (VRX) After Amgen (AMGN) Bows Out     9/2/2015
Exciting Time for Biotech in New Jersey     6/29/2015

News from Around the Web
How A $37,000-A-Year Medicine Sets A Good Model For Drug Pricing     4/4/2017
Why FDA Delay on Brodalumab is Actually Great News For Valeant (VRX)     11/30/2016
MorphoSys AG Moves Closer To Getting First Antibody Drug On Market     10/3/2016
Family History Biggest Predictor Of Heart Attacks In People With Psoriasis, University of Copenhagen Study     7/1/2016
Being Fat Ups Your Risk Of Getting This Skin Disease, University of Copenhagen Study     5/2/2016
Why It Feels So Good To Scratch An Itch, Published In Proceedings Of The Entomological Society Of Washington     2/29/2016
New Treatment for Psoriasis? Norwegian University of Science and Technology Study     1/14/2013
Analysis Links Psoriasis, Diabetes, University of California, Davis (UCD) Study     10/18/2012
Vigorous Exercise Might Keep Psoriasis at Bay, Brigham and Women's Hospital Study     5/22/2012
No Major Heart Risk Seen in New Psoriasis Drugs, Baylor Research Institute Study     8/24/2011
Study Sees Link Between Psoriasis, Obesity in Kids, Kaiser Permanente Reveals     5/23/2011
Antibody Efficacious in Psoriasis of the Hands and Feet, Central Dermatology Study     12/22/2010
Alcohol Linked to Psoriasis in Women, Harvard University Study     12/21/2010
NonLight Beer Consumption Linked to Psoriasis in Women, Brigham and Women's Hospital Study     8/17/2010
Psoriasis Linked To Higher Depression, Anxiety And Suicidal Feelings Risk, University of Pennsylvania Study     8/17/2010

Press Releases
Sun Pharma (SUNPHARMA.NS) Announces U.S. FDA Filing Acceptance Of Biologics License Application (BLA) For Tildrakizumab     5/24/2017
Kadmon Announces Publication Of Clinical Data Showing KD025 Improved Clinical Scores In Psoriasis Patients     4/12/2017
OWC Pharmaceutical Research Corp. Announces World-Wide Expression Of Interest In Its Cannabis-Based Topical Cream For Treatment Of Psoriasis And Other Skin Disorders     4/6/2017
Eli Lilly (LLY): New Report Reveals Little Progress On 2014 WHO Psoriasis Recommendations     4/4/2017
STRATA Skin Sciences Release: Psoriasis Drugs Among Leaders In Drug Side Effect Reporting     3/31/2017
U.S. FDA Approves Addition Of Moderate To Severe Fingernail Psoriasis Data To AbbVie (ABBV)s HUMIRA (Adalimumab) Prescribing Information     3/30/2017
Avillion Signs Clinical Co-Development Agreement With Merck & Co. (MRK) To Advance Anti IL-17 A/F Nanobody In Psoriasis     3/30/2017
Almirall And Sun Pharma (SUNPHARMA.NS) Announce Regulatory Filing Of Tildrakizumab In Europe     3/24/2017
MetrioPharm AG Announces Positive Top-Line Results From A Phase IIa Study In Moderate-To-Severe Psoriasis With Its Oral Lead Compound MP1032     3/14/2017
Dermira (DERM) And UCB Group (UCBJF.PK) Release: New CIMZIA (Certolizumab Pegol) Data In Moderate-To-Severe Plaque Psoriasis And Psoriatic Arthritis Presented At American Academy of Dermatology 2017 Annual Meeting     3/6/2017
Galectin (GALT)’s GR-MD-02 Demonstrates Efficacy In Patients With Moderate To Severe Plaque Psoriasis     3/6/2017
New Head-To-Head Data Shows Significantly Higher Response Rates For Eli Lilly (LLY) 's Taltz (Ixekizumab) Compared To Stelara (Ustekinumab) In Patients With Moderate-To-Severe Plaque Psoriasis     3/6/2017
Celgene (CELG) Release: Oral OTEZLA (Apremilast) Demonstrated Significant Improvement Versus Placebo In Trial Of Patients With Moderate Plaque Psoriasis Who Were Naïve To Systemic And Biologic Therapy     3/6/2017
Novartis AG (NVS)' Cosentyx Shows Almost All Psoriasis Patients Rapidly Regain Skin Clearance Following A Treatment Pause     3/6/2017
Janssen R&D Release: New Results From Second Phase III Study Show Significant Efficacy Of Guselkumab And Superiority Versus Humira In Treatment Of Moderate To Severe Plaque Psoriasis     3/3/2017

//-->